TOXPLUS Monitoring


TOXPLUS (founded January 2020) provides nonclinical drug development support for biotechnology and pharmaceutical companies. Services focus on toxicology and pharmacology support, nonclinical study management and monitoring (GLP and non-GLP), vendor audits, data review/QC, and regulatory writing for submissions such as IND/NDA nonclinical sections. The company offers global monitoring coverage and customized program support across small molecules, large molecules, and cell & gene therapy programs.

Industries

clinical-trials
life-science
pharmaceutical

Nr. of Employees

small (1-50)

TOXPLUS Monitoring

Chicago, Illinois, United States, North America


Services

Customized study management including CRO selection, protocol support, milestone tracking, data review, and report review/editing.

On-site and remote monitoring of nonclinical study conduct and data collection with configurable monitoring plans and regional coverage.

On-site or paper-based audits and qualification services for GLP and non-GLP CROs to assess compliance and study quality.

Toxicologist-led services including lead candidate selection support, study design input, data interpretation, program strategy, and participation in regulatory meetings.

Preparation and QC of regulatory documents including nonclinical sections of IND and NDA submissions, meeting packages, and tabulated summaries.

Expertise Areas

  • Nonclinical study management
  • Nonclinical study monitoring
  • Toxicology and pharmacology support
  • Regulatory writing for IND/NDA nonclinical sections
  • Show More (5)

Key Technologies

  • Good Laboratory Practice (GLP) compliance and oversight
  • Nonclinical study monitoring methodologies
  • Regulatory submission authoring (IND/NDA nonclinical modules)
  • CRO selection and vendor audit methodologies
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.